Welcome to our dedicated page for Compass Therapeutics news (Ticker: CMPX), a resource for investors and traders seeking the latest updates and insights on Compass Therapeutics stock.
About Compass Therapeutics Inc.
Compass Therapeutics Inc. (Nasdaq: CMPX) is a clinical-stage oncology-focused biopharmaceutical company dedicated to developing innovative antibody-based therapeutics to treat a range of cancers and other human diseases. Headquartered in Boston, Massachusetts, Compass leverages cutting-edge science to address the intricate relationship between angiogenesis, the immune system, and tumor growth. The company’s mission is to deliver transformative therapies that target critical biological pathways, enabling more effective anti-tumor responses.
Core Focus and Proprietary Platforms
Compass Therapeutics is at the forefront of antibody discovery and development, with a focus on bispecific antibodies, monoclonal antibodies, and engineered protein constructs. The company’s proprietary platforms, including StitchMabs and common light chain technologies, empower researchers to empirically identify optimal drug combinations. This approach allows for rapid translation of preclinical insights into tailored therapeutics with monoclonal-like manufacturability, positioning Compass as a leader in the field of combinatorial immunotherapy.
Pipeline and Clinical Programs
Compass Therapeutics boasts a robust pipeline targeting multiple critical pathways involved in tumor progression and immune evasion:
- Tovecimig (CTX-009): A bispecific antibody targeting DLL4 and VEGF-A, designed to inhibit angiogenesis and tumor vascularization. Currently in Phase 2/3 clinical trials for advanced biliary tract cancers (BTC) and being evaluated for additional indications like colorectal cancer (CRC).
- CTX-471: A novel CD137 agonist antibody that activates immune effector cells within the tumor microenvironment. Early clinical results suggest potential efficacy in melanoma, small-cell lung cancer, and mesothelioma, with biomarker-driven Phase 2 trials planned.
- CTX-8371: A next-generation bispecific checkpoint inhibitor targeting PD-1 and PD-L1, with a unique mechanism involving proteolytic cleavage of cell surface PD-1. This program is in Phase 1 trials for solid tumors.
- CTX-10726: A newly announced PD-1 x VEGF-A bispecific antibody advancing through preclinical development, with an IND submission expected by year-end 2025.
These candidates reflect Compass’s commitment to addressing high unmet medical needs, particularly in patient populations resistant to existing therapies.
Scientific Excellence and Biomarker-Driven Strategy
Compass Therapeutics integrates biomarker-driven strategies into its clinical development programs. For example, the identification of NCAM (CD56) as a potential biomarker for CTX-471 highlights the company’s ability to leverage cutting-edge science to enhance patient selection and therapeutic efficacy. Similarly, the use of DLL4 as a biomarker in CRC studies underscores Compass’s precision medicine approach.
Collaborative and Industrialized Approach
The company’s “partnership-first” mentality enables it to collaborate with top-tier academic institutions and leverage best-in-class technologies. This decentralized validation model accelerates the transition from discovery to clinical development, ensuring that only the most promising therapeutic combinations advance to human trials.
Competitive Landscape and Market Position
Operating in the highly competitive field of oncology-focused biopharmaceuticals, Compass Therapeutics distinguishes itself through its emphasis on bispecific antibodies and its robust biomarker-driven approach. Competitors include established players like Genentech and Bristol Myers Squibb, but Compass’s focus on immune-oncology and angiogenesis modulation positions it uniquely within the market. The company’s ability to identify and exploit novel biological pathways gives it a competitive edge in addressing complex cancer mechanisms.
Challenges and Opportunities
While Compass Therapeutics faces challenges typical of clinical-stage biopharma companies—such as regulatory hurdles and the inherent risks of drug development—it is well-positioned to overcome these obstacles through its innovative platforms, strong clinical pipeline, and strategic collaborations. The growing emphasis on immuno-oncology and biomarker-driven therapies provides significant opportunities for the company to expand its impact and market presence.
Conclusion
Compass Therapeutics Inc. exemplifies innovation and scientific rigor in the biopharmaceutical industry. With a robust pipeline, proprietary technologies, and a focus on addressing unmet medical needs, the company is poised to make significant contributions to the field of oncology. By targeting critical pathways involved in tumor growth and immune modulation, Compass is advancing the next generation of cancer therapeutics, offering hope to patients worldwide.
Compass Therapeutics (CMPX) announced several advancements in its clinical pipeline, including the initiation of U.S. Phase 2/3 trials for CTX-009 targeting advanced biliary tract cancers (BTC) and colorectal cancer (CRC). The company presented promising Phase 2 results at the 2023 ASCO GI Cancers Symposium, reporting a 37.5% overall response rate (ORR) in BTC patients. Financially, Compass ended 2022 with $187 million in cash, ensuring a runway until 2026. The net loss for the year was $39.2 million, a reduction from $82.2 million in 2021 due to decreased non-recurrent R&D expenses. Initial results from current trials are expected in 2023 and 2024.
BOSTON, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX) announced its participation in the SVB Securities Global Biopharma Conference, scheduled for February 13-16, 2023. A significant event will be the fireside chat on February 15 at 11:20 AM ET, accessible via a live webcast. Investors can view the archived presentation for 90 days on the Company’s Events page. Compass Therapeutics focuses on developing proprietary antibody-based therapeutics targeting oncology and aims to advance its products through clinical development, addressing critical biological pathways for effective anti-tumor responses.
Compass Therapeutics, Inc. (Nasdaq: CMPX) announced promising data from a Phase 2 study of CTX-009 combined with paclitaxel for biliary tract cancers (BTC). The study revealed a 37.5% overall response rate (ORR) across all 24 patients, with a notable 63.6% ORR in the second-line subgroup. Median progression-free survival (PFS) was 9.4 months and overall survival (OS) was 12.5 months. Safety profiles were consistent with prior studies, as 95.8% of patients experienced grade 3 or higher treatment-emergent adverse events. A randomized Phase 2/3 trial of CTX-009 in the U.S. has been initiated, potentially supporting a biologics license application in 2024.
Compass Therapeutics, Inc. (Nasdaq: CMPX) has announced the dosing of the first patient in a Phase 2 clinical study of CTX-009 for metastatic colorectal cancer. This study targets patients who have undergone at least two previous therapies and will evaluate safety and clinical response. The drug is designed to block critical cancer pathways, with prior Phase 1 studies showing confirmed responses. Preliminary results are expected mid-2023, marking a significant development in treatment options for patients facing limited therapies.
Compass Therapeutics, Inc. (CMPX) announced updated Phase 2 study results for CTX-009 combined with paclitaxel in biliary tract cancer (BTC) to be presented at the 2023 ASCO GI Symposium in San Francisco, January 19-21. The event will also showcase ongoing studies including a Phase 2/3 trial for BTC and a Phase 2 trial for metastatic colorectal cancer (CRC).
The presentations aim to highlight the therapeutic potential of CTX-009, which targets DLL4 and VEGF A, and its impact on patient outcomes.
Compass Therapeutics (Nasdaq: CMPX) announced the first patient dosed in a Phase 1b study of CTX-471 combined with KEYTRUDA® for treating advanced solid tumors, including lung and head & neck cancers.
The study aims to evaluate CTX-471's ability to restore responses after checkpoint inhibitor therapy. Previous monotherapy results showed signs of activity.
CTX-471 is a CD137 agonist that activates key immune cells. Four partial responses were observed in earlier trials as of September 30, 2022.
Compass Therapeutics, a clinical-stage biopharmaceutical company focused on cancer treatment, will participate in the Piper Sandler 34th Annual Healthcare Conference from November 29 to December 1, 2022, in New York City. The company's presentation is scheduled for December 1, 2022, at 8:50 AM ET. A webcast link will be available on their website, and the corporate presentation will be archived for 90 days. Compass Therapeutics is dedicated to developing antibody-based therapies targeting key biological pathways to enhance anti-tumor responses.
Compass Therapeutics (CMPX) announced financial results for Q3 2022, reporting a net loss of $12 million, or $0.12 per share, compared to $6 million, or $0.10 per share, in Q3 2021. Cash and marketable securities were $120.6 million, down from $144.5 million at the end of 2021. The company raised approximately $80 million through a PIPE financing to extend its cash runway into 2026. Key clinical trials for CTX-009 and CTX-471 are underway, with patient enrollment expected to start in Q4 2022. R&D expenses surged by 210% year-over-year, reflecting increased development activities.
BOSTON, Nov. 08, 2022 - Compass Therapeutics, Inc. (Nasdaq: CMPX) announced its participation in two key investor conferences this November. The Stifel Healthcare Conference in New York City is scheduled for November 15, 2022, from 4:10-4:40 PM ET. The Jefferies Global Healthcare Conference in London will take place on November 16, 2022, from 3:15-3:45 PM GMT. Both presentations will be available via webcast, with a replay accessible for 90 days. Compass Therapeutics focuses on developing antibody-based therapies targeting cancer.
Compass Therapeutics, Inc. (CMPX) announced a private investment in public equity (PIPE) financing, selling 25 million shares at $3.21 each, totaling approximately $80 million. The financing, led by Enavate Sciences and other institutional investors, is expected to close by November 8, 2022. Funds will advance their clinical pipeline, including CTX-009, CTX-471, and CTX-8371, extending the company's cash runway into 2026. The securities have not been registered under the Securities Act but will be subject to a registration rights agreement for resale.
FAQ
What is the current stock price of Compass Therapeutics (CMPX)?
What is the market cap of Compass Therapeutics (CMPX)?
What does Compass Therapeutics Inc. specialize in?
What are Compass Therapeutics’ key pipeline products?
How does Compass Therapeutics differentiate itself in the oncology market?
What is the significance of biomarkers in Compass’s clinical programs?
What challenges does Compass Therapeutics face?
What is the company’s approach to collaboration?
What are the clinical applications of Tovecimig (CTX-009)?
What is CTX-471, and how does it work?
